Tisdag 17 November | 13:01:27 Europe / Stockholm
Est. tid*
2026-08-31 - Kvartalsrapport 2026-Q2
2026-08-25 - Extra Bolagsstämma 2026
2026-05-11 - X-dag ordinarie utdelning CRNA 0.00 NOK
2026-05-08 - Årsstämma
2026-04-15 - Bokslutskommuniké 2025
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma
LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades år 2010 och har sitt huvudkontor i Lysaker.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

CRNA: Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease

2026-11-11 07:00:07
* The collaboration will evaluate combining the circVec generation 5 construct
into POLARIS-101TM to address major unmet medical needs in genetic heart
disease
* Solid Biosciences proprietary, next-generation AAV capsid, POLARIS-101, was
engineered for enhanced cardiac and muscle tropism
* Circio s latest circVec generation 5 has demonstrated up to 200-fold
enhanced gene expression from AAV vectors in heart in vivo

Oslo, Norway, 11 November 2026 -- Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces a research collaboration with Solid
Biosciences Inc. (Nasdaq: SLDB) to evaluate the combination of Circio's
circVec platform with Solid's proprietary, next-generation AAV capsid,
POLARIS-101TM, for targeted, systemic gene therapy for genetic heart disease.

Current gene therapy approaches for genetic heart disease often require high
systemic AAV doses associated with significant safety risks. Circio s circular
RNA gene expression platform, circVec, has demonstrated approximately 200-fold
enhanced gene expression from AAV vectors in the heart in vivo. Solid s
proprietary myotropic capsid, POLARIS-101, was engineered for enhanced cardiac
muscle targeting with reduced liver biodistribution, and has generated
encouraging early clinical safety data.

The parties aim to integrate these complementary technologies to evaluate
potential synergies. The combination could result in highly specific and
potent next generation gene therapies to address major unmet medical needs in
genetic heart disease, with the intent of reducing therapeutic dose levels and
improving safety.

"Solid Biosciences is at the forefront of AAV engineering, and their
engineered capsid, POLARIS-101, has shown impressive cardiac targeting in
pre-clinical models, in addition to encouraging clinical safety data. We
believe that circVec can build on POLARIS-101's strong tropism to further
amplify cardiac gene expression, potentially enabling next generation heart
gene therapies with enhanced potency and specificity," said Dr. Victor
Levitsky, CSO of Circio. "Combining circVec with POLARIS-101 is a
strategically and scientifically highly relevant opportunity for Circio, and
we look forward to working with Solid s team of AAV experts. This R&D
collaboration adds further to our strategy of testing circVec in multiple
therapeutic applications, and broadens the development opportunities in
genetic heart disease."

In the collaboration, Circio will generate circVec constructs based on its
latest generation 5 design, which Solid will package using its proprietary
POLARIS-101 AAV capsid and dual plasmid manufacturing platform. The parties
will jointly characterize and test the combined AAV vectors in vitro and in
vivo. If successful, potential therapeutic candidates will be further
evaluated and progressed into pre-clinical development. The collaboration is
part of Circio s R&D strategy to test circVec with complementary,
state-of-the-art delivery solutions to design next generation therapy vectors
with improved performance and specificity for heart, eye and CNS tissues.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR
Phone: +44 782 125 5568
Email: neiljameshunter@gmail.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 60-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.
gy. The\
circVec R&D activities are being conducted by the wholly owned subsidiary\
Circio AB in Stockholm\, Sweden.\